BioSpace News Archive

BrainStorm Cell Therapeutics Inc., a leading developer of cellular therapies for neurodegenerative diseases, announced financial results for the second quarter and first half ended June 30, 2020, and provided a corporate update.

Strategic Transaction Enhances Farm-to-Table Animal Traceability Solutions for Livestock and Aquaculture

Hepion Pharmaceuticals, Inc., a biopharmaceutical company focusing on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis, announced that CRV431 was administered to the first NASH patient.

Revenues of $3.9 billion GAAP diluted EPS of $0.13 Non-GAAP diluted EPS of $0.55 Free cash flow of $582 million Full year 2020 business outlook reaffirmed: Net revenues of $16.6 - $17 billion EBITDA of $4.5 - $4.9 billion EPS of $2.30 - $2.55 Free cash flow of $1.8 - $2.2 billion

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ to treat serious neurologically mediated conditions, announced that management will participate in a virtual fireside chat, as well as host virtual investor meetings, at the 2020 BTIG Biotechnology Conference on August 10, 2020:

Daré Bioscience, Inc., a leader in women’s health innovation, announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Wednesday, August 12, 2020, to review its financial results for the quarter ended June 30, 2020 and to provide a Company update.

Spectral Medical Inc., a late stage theranostic company advancing therapeutic options for sepsis and septic shock, provided a corporate update on its Tigris trial, COVID-19 initiatives, EAA launch, and Dialco regulatory activities.

Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Officer of the Company, will present virtually at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11 th at 11:30am ET and at the Canaccord Genuity 40 th Annual Growth Conference on We

KBP-5074 Being Evaluated for the Treatment of Uncontrolled Hypertension in Advanced Chronic Kidney Disease (CKD) Patients Top-Line Data on Track for Fourth Quarter of 2020

Empagliflozin significantly reduced the risk of cardiovascular death or hospitalization for heart failure versus placebo in the EMPEROR-Reduced heart failure trial. The study evaluated adults with heart failure with reduced ejection fraction